Peripheral Reservoir of HIV DNA in Monocytes Pivotal to Cognition in HIV
This study has been completed.
Information provided by (Responsible Party):
Assoc.Prof.Jintanat Ananworanich, M.D., South East Asia Research Collaboration with Hawaii
First received: October 29, 2008
Last updated: September 25, 2014
Last verified: September 2014
Sixty HIV participants will be enrolled and stratified by PBMC HIV DNA levels, either high (greater than or equal to 5000 copies/106 cells) or low (less than 5000 copies/106 cells). Individuals will be enrolled into each group until filled. Screening PBMC HIV DNA levels will be performed at SEARCH in real-time with less than one-week turn around time. All individuals will intend to initiate ARV due to meeting MOPH guidelines for such. The protocol team will work with the primary care physician to facilitate initiation of standard ARV care; however, initiation of ARV is not a requirement of the study and ARV will not be provided by the study.
||Observational Model: Cohort
Time Perspective: Prospective
Primary Outcome Measures:
- To determine the long-term relationship between cognition and HIV DNA in circulating PBMCs and monocytes (CD14+ PBMCs) among patients initiating HAART for the first time [ Time Frame: After March 30, 2016 ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||January 2014 (Final data collection date for primary outcome measure)
1 HIV DNA will be stratified by high
2 HIV DNA will be stratified by low
|Ages Eligible for Study:
||20 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
HIV-infected individuals meeting MOPH criteria to initiate HAART and planning to initiate HAART within a month of screening. Consequently, all participants will have plasma CD4 counts at less than 250 cells.
- HIV-infected individuals meeting MOPH criteria to initiate HAART and planning to initiate HAART within a month of screening.
- Consequently, all participants will have plasma CD4 counts at less than 250 cells.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00782808
|Bangkok, Thailand |
South East Asia Research Collaboration with Hawaii
||Victor Valcour, MD
||University of Hawii
No publications provided
||Assoc.Prof.Jintanat Ananworanich, M.D., Assoc.Prof, South East Asia Research Collaboration with Hawaii
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 29, 2008
||September 25, 2014
||Thailand: Ethical Committee
Keywords provided by South East Asia Research Collaboration with Hawaii:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 25, 2014
Acquired Immunodeficiency Syndrome
Immune System Diseases
Immunologic Deficiency Syndromes
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases